Thrasos Therapeutics (Canada), a clinical-stage pharma company focused on acute kidney injury, closed a $35M Series C financing. Participants include SR One, GSK Canada Life Sciences Innovation Fund, Advanced Technology Ventures, Fonds de solidarité FTQ, Lumira Capital, MP Healthcare Venture Management and Pappas Ventures. ___________ Collective IP | The Most Comprehensive and Accurate View of […]
Promethera Biosciences (Belgium) a clinical stage biotechnology company focused on adult stem cell treatments for liver diseases, closed a $31.4 Series B financing. Participants include Vesalius Biocapital, SRIW, Vives-Louvain Technology Fund, Life Science Research Partners, NivelInvest, Sopartec, Boehringer Ingelheim Ventures, Shire Ventures, Mitsui Global Investment, ATMI and Sambrinvest. Note: Closing out 1Q deals. Thanx for […]
Promethera Biosciences (Belgium) a development-stage stem cell therapy company focused on liver diseases, closed a $7.3M Series A financing. Participants include Vesalius Biocapital, Société Régionale d’Investissement de Wallonie, Life Sciences Partners, NivelInvest, Capital & Croissance, LRM, Vives and Sopartec. Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb
Hyperion Therapeutics (San Francisco, CA) a clinical-stage specialty pharmaceutical company focused on gastroenterology and hepatology, closed a $60M Series C financing. Participants include Bay City Capital, Panorama Capital, Highland Capital Partners, New Enterprise Associates, Sofinnova Ventures, and WRF Capital.